MedTrace Logo

Effects of Chromium on Insulin Resistance in Alzheimer Disease Patients

NCT03038282 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-01-31

No results posted yet for this study

Summary

The effect of Chromium to improve glucose levels in Alzheimer Disease (AD) is controversial. The hypothesis of the study is to evaluate the effect of supplementing the AD individuals with Chromium combined with exercise and assessing the effect of the supplementation on glucose metabolism.

Conditions

  • Alzheimer Disease

Interventions

DIETARY_SUPPLEMENT

Chromium Chloride

Transdermal chromium chloride 50 to 600 mcg/day.

OTHER

Individual Exercise

Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks

Sponsors & Collaborators

  • Metabolic Therapy Inc.

    lead OTHER

Principal Investigators

  • Andreana Haley, PhD · University of Texas - Austin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-20
Primary Completion
2019-08-20
Completion
2019-10-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03038282 on ClinicalTrials.gov